Cue Biopharma Inc (CUE)
1.705
+0.22
(+14.81%)
USD |
NASDAQ |
Nov 05, 16:00
1.74
+0.04
(+2.05%)
After-Hours: 19:03
Cue Biopharma Total Liabilities (Quarterly): 20.71M for June 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 20.71M |
| March 31, 2024 | 23.91M |
| December 31, 2023 | 24.44M |
| September 30, 2023 | 26.22M |
| June 30, 2023 | 27.16M |
| March 31, 2023 | 26.66M |
| December 31, 2022 | 25.60M |
| September 30, 2022 | 25.54M |
| June 30, 2022 | 24.99M |
| March 31, 2022 | 26.03M |
| December 31, 2021 | 17.91M |
| September 30, 2021 | 15.36M |
| June 30, 2021 | 16.76M |
| March 31, 2021 | 19.05M |
| December 31, 2020 | 20.62M |
| Date | Value |
|---|---|
| September 30, 2020 | 19.06M |
| June 30, 2020 | 21.20M |
| March 31, 2020 | 15.41M |
| December 31, 2019 | 17.02M |
| September 30, 2019 | 18.19M |
| June 30, 2019 | 21.48M |
| March 31, 2019 | 20.45M |
| December 31, 2018 | 11.39M |
| September 30, 2018 | 5.178M |
| June 30, 2018 | 3.882M |
| March 31, 2018 | 4.084M |
| December 31, 2017 | 5.347M |
| September 30, 2017 | 1.915M |
| June 30, 2017 | 1.580M |
| December 31, 2016 | 1.104M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
15.36M
Minimum
Sep 2021
27.16M
Maximum
Jun 2023
21.77M
Average
21.20M
Median
Jun 2020
Total Liabilities (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 1.438B |
| Arbutus Biopharma Corp | 37.59M |
| GlycoMimetics Inc | 4.356M |
| FibroGen Inc | 483.58M |
| Cidara Therapeutics Inc | 42.42M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 42.33M |
| Shareholders Equity (Quarterly) | 21.62M |
| Debt to Equity Ratio | 0.289 |
| Current Ratio | 2.060 |
| Net Debt Paydown Yield | 1.26% |